"Receptors, CXCR4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
CXCR receptors with specificity for CXCL12 CHEMOKINE. The receptors may play a role in HEMATOPOIESIS regulation and can also function as coreceptors for the HUMAN IMMUNODEFICIENCY VIRUS.
Descriptor ID |
D019718
|
MeSH Number(s) |
D12.776.543.750.695.160.500.400 D12.776.543.750.705.852.125.500.400 D12.776.543.750.830.700.650
|
Concept/Terms |
Receptors, CXCR4- Receptors, CXCR4
- LESTR Receptor
- CXC Chemokine Receptor 4
- Fusin
- CXCR4 Receptor
- Receptor, CXCR4
- CXCR4 Receptors
- Leukocyte-Derived Seven-Transmembrane Domain Receptor
- Leukocyte Derived Seven Transmembrane Domain Receptor
- Receptor, LESTR
|
Below are MeSH descriptors whose meaning is more general than "Receptors, CXCR4".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Chemokine [D12.776.543.750.695.160]
- Receptors, CXCR [D12.776.543.750.695.160.500]
- Receptors, CXCR4 [D12.776.543.750.695.160.500.400]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Chemokine [D12.776.543.750.705.852.125]
- Receptors, CXCR [D12.776.543.750.705.852.125.500]
- Receptors, CXCR4 [D12.776.543.750.705.852.125.500.400]
- Receptors, Virus [D12.776.543.750.830]
- Receptors, HIV [D12.776.543.750.830.700]
- Receptors, CXCR4 [D12.776.543.750.830.700.650]
Below are MeSH descriptors whose meaning is more specific than "Receptors, CXCR4".
This graph shows the total number of publications written about "Receptors, CXCR4" by people in this website by year, and whether "Receptors, CXCR4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
2000 | 0 | 1 | 1 |
2002 | 2 | 0 | 2 |
2003 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2005 | 0 | 3 | 3 |
2006 | 0 | 1 | 1 |
2007 | 1 | 1 | 2 |
2008 | 1 | 1 | 2 |
2009 | 0 | 1 | 1 |
2010 | 2 | 0 | 2 |
2012 | 1 | 1 | 2 |
2013 | 2 | 2 | 4 |
2015 | 1 | 1 | 2 |
2016 | 1 | 2 | 3 |
2017 | 1 | 0 | 1 |
2018 | 1 | 0 | 1 |
2019 | 3 | 0 | 3 |
2020 | 0 | 1 | 1 |
2021 | 2 | 0 | 2 |
2022 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, CXCR4" by people in Profiles.
-
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis. Mol Cancer. 2023 01 04; 22(1):1.
-
Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias. Sci Adv. 2022 07 15; 8(28):eabn8063.
-
Type 1 diabetes patients increase CXCR4+ and CXCR7+ haematopoietic and endothelial progenitor cells with exercise, but the response is attenuated. Sci Rep. 2021 07 15; 11(1):14502.
-
Hypoxia Preconditioning Promotes the Proliferation and Migration of Human Urine-Derived Stem Cells in Chronically Injured Liver of Mice by Upregulating CXCR4. Stem Cells Dev. 2021 05 15; 30(10):526-536.
-
Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J Clin Oncol. 2020 11 01; 38(31):3672-3684.
-
CXCR4 signaling directs Igk recombination and the molecular mechanisms of late B lymphopoiesis. Nat Immunol. 2019 10; 20(10):1393-1403.
-
Defining Genetic Variation in Widely Used Congenic and Backcrossed Mouse Models Reveals Varied Regulation of Genes Important for Immune Responses. Immunity. 2019 07 16; 51(1):155-168.e5.
-
Plerixafor for the Treatment of WHIM Syndrome. N Engl J Med. 2019 01 10; 380(2):163-170.
-
Dynamins 2 and 3 control the migration of human megakaryocytes by regulating CXCR4 surface expression and ITGB1 activity. Blood Adv. 2018 12 11; 2(23):3540-3552.
-
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs. 2017 06; 35(3):334-344.